Haloperidol decanoate 100 mg

Haloperidol is a typical butyrophenone type antipsychotic that exhibits high affinity dopamine D 2 receptor antagonism and slow receptor dissociation kinetics. [41] It has effects similar to the phenothiazines . [17] The drug binds preferentially to D 2 and α 1 receptors at low dose (ED 50 = and  mg/kg, respectively), and 5-HT 2 receptors at a higher dose (ED 50 =  mg/kg). Given that antagonism of D 2 receptors is more beneficial on the positive symptoms of schizophrenia and antagonism of 5-HT 2 receptors on the negative symptoms, this characteristic underlies haloperidol's greater effect on delusions, hallucinations and other manifestations of psychosis. [42] Haloperidol's negligible affinity for histamine H 1 receptors and muscarinic M 1 acetylcholine receptors yields an antipsychotic with a lower incidence of sedation, weight gain, and orthostatic hypotension though having higher rates of treatment emergent extrapyramidal symptoms .

Ensure patient is maintained on specific manufacturer's product (MHRA 2013).
No monitoring of drug levels required to optimise or to monitor treatment.
Prescriptions for phenobarbital (phenobarbitone) must comply with the following legal requirements:

  • the prescription must be signed and dated by the prescriber.
  • the handwritten or computer-generated script must state:
    • the name and address of the patient.
    • the form and strength of the preparation.
    • the dose (note “as directed” does not constitute a dose).
    • the total quantity of the preparation in words and figures.

The intravenous route is not FDA approved and is generally not recommended except when no other alternatives are available. Intravenous administration appears to be associated with a higher risk of QT prolongation and torsade de pointes (TdP) than other forms of administration. The manufacturer recommends ECG monitoring for QT prolongation and arrhythmias if IV administration is required. A dose in the range of 1 to 5 mg IV has been suggested, with the dose being repeated at 30 to 60 minute intervals, if needed. A maximum IV dose has not been established. The lowest effective dose should be used in conjunction with conversion to oral therapy as soon as possible.

Haloperidol decanoate 100 mg

haloperidol decanoate 100 mg


haloperidol decanoate 100 mghaloperidol decanoate 100 mghaloperidol decanoate 100 mghaloperidol decanoate 100 mghaloperidol decanoate 100 mg